Concept

G2 phase

Related people (28)

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Bart Deplancke

Urs von Stockar

Originaire de Zurich, Urs von Stockar est né en1942. Ingénieur chimiste diplômé de l'EPFZ en 1967, il y est ensuite assistant au Laboratoire de chimie technique et, en 1973, soutient sa thèse couronnée par la médaille d'argent de l'EPFZ. De 1973 à 1976, il travaille au département de génie chimique de l'Université de Californie. Il y enseigne et participe au développement d'un procédé technique pour la conversion biologique de la cellulose en alcool. En 1977, il est ingénieur chimiste chez Ciba-Geigy. Fin 1977 il est nommé professeur extraordinaire à l'EPFL. Il dirige l'Institut de génie chimique en 1978/79 et en 1989/90. Il est professeur ordinaire en 1982. En 1982/83 et 1993/95, il dirige le Département de chimie. Son enseignement et sa recherche traitent des opérations de transfert de masse et de la biotechnologie, il s'intéresse également aux questions de bioénergétique et de biothermodynamique. Collaborant avec l'UNIL et l'ISREC, son équipe développe des procédés de fabrication d'anticorps monoclônaux spéciaux, capables de protéger les muqueuses humaines. En 1990 il est nommé professeur associé à l'Université de Genève. Il représente la Suisse dans un groupe d'experts de la Fédération européenne de biotechnologie. Après avoir siégé pendant plusieurs années dans son Comité de direction, il a été nommé président de la Fédération Européenne de Biotechnologie pour la période 1996-97. Depuis 1991, il dirige le Comité de coordination suisse pour la biotechnologie. Diploma in Chemical Eng.-1967-ETHZ, CH Ph.D.-1972-ETHZ, CH Postdoc. Fellow-1973-76-Univ. of California, Berkeley, US

Daniele Mari

Daniele Mari was born in Milan in 1961, After a scientific high school degree obatained in Italy Daniele Mari joins EPFL in 1980 and graduates in Physics in 1986. In 1991, he obtains the Ph.D. from the same institution working in the field of metal-ceramic composites. From 1992 to 1993 he continues his research as a post-doc at the Massachusetts Institute of Technology with a work on shape-memory alloys. In 1993, he joins the company Amysa Yverdon SA (Switzerland) as director of Research and Development and creates ACME (Advanced Composite & Microwave Engineering) with activities in the fields of the electromagnetic heating and materials science. In parallel with his industrial activities, D. Mari has supervised different research projects in materials science at the EPFL. In 2004 he joins the Laboratoire de Physique de la Matière Complexe to develop mechanical spectroscopy in the field of hard materials and steels. He is appointed MER in 2012. Since then he is responsible for the Physics Laboratories (for student training) and Auditoriums. Since 2013 D. Mari is the Deputy Director of the Physics School.

David Hacker

Nicolas Fournier

Jan Van Herle

Born in Antwerp, Belgium. In Switzerland since 1983. Became Swiss citizen in 2004 out of conviction of principles of democracy and bottom-up participation. No double nationality. Village Council Member for 2 five-year mandates in 2006-2016. 1987 : Chemist from Basel University (CH). 1988 : Post-graduate IT diploma from Basel Engineering School. 1989 : Industry internship ABB Baden (CH). 1990-1993 : PhD Thesis EPFL, on Solid Oxide Fuel Cell cathode reaction mechanisms. 1994-1995 : Japanese Postdoctoral Fellowship in Tsukuba, Japan, on ceramic powders. 1995-2000 : Researcher at EPFL, Dpt. Chemistry : project responsible in PPM2 (materials), FP4-BriteEuram, NEDO (Japan), Swiss Gas Union (CH, oxygen membranes). 1998-2000 : Masters in Energy Technology, EPFL. 2000 : Cofounder of HTceramix SA (EPFL spin-off), now based in Yverdon (14 employees). Taken over by SOLIDpower in 2007, now 250 employees with 70 MCHF raised. 2000 : 1st Assistant and lecturer at LENI (STI-IGM) : fuel cell group responsible, projects on biogas (Federal Energy Office), woodgas (CCEM), fuel cell stacking (CTI, FP6, FNS), ceramic separation membranes (COST, FNS), microtubes (STI Seed), stability/lifetime/reliability in fuel cells (Electricité de France, swisselectric research). Currently 4 Ph D theses ongoing, 14 theses concluded, of which 5 colateral with SB and IMX. M.E.R. since Nov 2008. Total funding raised so far >18 MCHF (50% as main applicant; 30% outside CH; 20% industry). Scientific output : >135 peer-reviewed publications, >120 conference papers, 40 invited presentations (8 keynotes), >70 granted proposals. Fluent in 5 languages (Dutch, French, German ( Swiss-german), English, Spanish).

Francesco Varrato

Hilal Lashuel

2012-2013 Visiting Professor, Standford University. Stanford School of Medicine 2011- Associate Professor of Life Sciences-Brain Mind Institute-EPFL Dir. Laboratory of Chemical Biology of Neurodegeneration 2005-2011 Assistant Professor of Life Sciences-Brain Mind Institute-EPFL Dir. Laboratory of Molecular Neurobiology and Neuroproteomics 2005-2008 Director- EPFL Proteomic Core Facility 2002-2004 Instructor of Neurology- Harvard Medical School and Brigham and Women's Hospital 2001-2002 Sabbatical Fellow- Laboratory for Drug Discovery in Neurodegeneration Harvard Medical School, 2001-2002 Post-doctoral Fellow- Center for Neurologic Diseases Harvard Medical School and Brigham and Women's Hospital Advisor- Prof. Peter T. Lansbury 2000-2001 Research Scientist, The Picower Institute for Medical Research, Great Neck New York 1994-2000 PhD Student; Texas A&M University and the Scripps Research Institute Advisor- Prof. Jeffery W. Kelly 1990-1994 B.S. City University of New York, Brooklyn College Dr. Hilal A. Lashuel received his B.Sc. degree in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. After obtaining his doctoral degree, he became a research fellow at the Picower Institute for Medical Research in Long Island New York. In 2001, he moved to Harvard Medical School and the Brigham and Women's Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. During his tenure (2001-2004) at Harvard Medical School his work focused on understanding the mechanisms of protein misfolding and fibrillogenesis and the role of these processes in the pathogenesis of Parkinson's and Alzheimer's disease. In 2005 Dr. Lashuel moved Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne as a tenure-track assistant professor in neurosciences. Currently, Dr. Lashuel is an associate professor of life sciences and the director of the laboratory of molecular and chemical biology of neurodegeneration. (http://lashuel-lab.epfl.ch/). Research efforts in the Lashuels laboratory focus on understanding the molecular mechanisms of neurodegeneration and developing novel strategies to diagnose and treat neurodegenerative diseases such as Alzheimers and Parkinsons disease. Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntingtons disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson. Dr. Lashuels research has resulted in the characterization of novel quaternary structure intermediates on the amyloid pathway, identification of potential therapeutic targets, and new hypotheses concerning the mechanisms of pathogenesis in Alzheimers disease, Parkinsons disease and related disorders. Dr. Lashuel scientific contribution to this field includes i) more than100 publications in major peer reviewed journals including Nature journals, Cell, PNAS, JBC, J. Neuroscience JACS, and Angewandtie Chemie; ii) three patents on novel strategies for preventing protein aggregation and treating autoimmune and inflammatory diseases; iii) more than 150 invited lectures since 2002 and more than 5500 citations (7800 citation-Google Scholar) since 1996. Dr. Lashuel has received several pre-doctoral and post-doctoral awards and fellowships and was the recipient of two prestigious awards given to young investigators; Human Science Frontiers young investigator research award and the European Research Council (ERC) starting independent researcher grant and the ERC proof of concept award (2013) These awards provide more than $2.5 Million to Dr. Lashuel to translate some of his ideas and projects into novel strategies for diagnosing and treating neurodegenerative diseases such as Alzheimers and Parkinsons disease. Dr. Lashuel has chaired and co-organized several international conferences and serves as an academic editor for PLoS ONE, an associate editor for frontiers of molecular neuroscience, member of the Editorial advisory board of ChemBioChem and ad hoc reviewer for several international scientific journals and funding agencies.

Olivier Sauter

Giovanni Dietler